TuisNOVN • SWX
add
Novartis AG
Vorige sluiting
CHF 91,56
Dagwisseling
CHF 92,04 - CHF 93,99
Jaarwisseling
CHF 83,63 - CHF 102,72
Markkapitalisasie
205,76 mjd CHF
Gemiddelde volume
2,97 m
P/V-verhouding
12,39
Dividend-opbrengs
3,52%
Primêre beurs
SWX
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 13,17 mjd | 8,93% |
Bedryfskoste | 5,52 mjd | -24,45% |
Netto inkomste | 3,19 mjd | 81,09% |
Netto winsgrens | 24,21 | 66,28% |
Wins per aandeel | 2,06 | 18,39% |
EBITDA | 5,50 mjd | 88,62% |
Effektiewe belastingkoers | 5,91% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 13,85 mjd | 8,08% |
Totale bates | 103,52 mjd | -8,14% |
Totale aanspreeklikheid | 60,08 mjd | -19,30% |
Totale ekwiteit | 43,44 mjd | — |
Uitstaande aandele | 2,00 mjd | — |
Prys om te bespreek | 4,23 | — |
Opbrengs op bates | 10,97% | — |
Opbrengs op kapitaal | 15,05% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 3,19 mjd | 81,09% |
Kontant van bedrywe | 6,29 mjd | 16,88% |
Kontant van beleggings | -374,00 m | 83,09% |
Kontant van finansiering | -382,00 m | 54,09% |
Netto kontantverandering | 5,71 mjd | 275,39% |
Beskikbare kontantvloei | 4,55 mjd | -63,57% |
Meer oor
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, “novae artes”.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
Gestig
29 Feb. 1996
Hoofkwartier
Webwerf
Werknemers
76 057